Pharmaceutical Executive
A follow-up survey of clinical and financial health plan leaders uncovers evolving approaches and views on the management of high-cost, curative-intended treatments with one-time administration.
Matt W. Courtney
Advertisement
Articles by Matt W. Courtney
Pharmaceutical Executive
A look at two surveys that reveal payer perspectives regarding current and future management of high-cost durable therapies with one-time administration.
Advertisement
Latest Updated Articles
Payer Perspectives on Gene Therapy ReimbursementApril 8th 2020
Advertisement
Advertisement
Trending on PharmExec
1
TrumpRx Selling Medicines at Higher Prices Than Other Countries: Report
2
What Pharma Marketers Need to Know About Recent Gartner Predictions About AI and What It Means to Them
3
Pharmaceutical Executive Daily: Analysis on TrumpRx List Pricing
4
Conflict in Middle East Disrupts Pharma Drug Supplies: Report
5